What is a stock summary page? Click here for an overview.
Business Description
Adaptimmune Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00653A1079
Share Class Description:
ADAP: ADRDescription
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.04 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 6.26 | |||||
| Debt-to-EBITDA | -1.38 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -5.59 | |||||
| Beneish M-Score | -0.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 162.6 | |||||
| 3-Year EBITDA Growth Rate | 40.6 | |||||
| 3-Year EPS without NRI Growth Rate | 37.3 | |||||
| 3-Year Book Growth Rate | -67.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 8.37 | |||||
| 9-Day RSI | 12.14 | |||||
| 14-Day RSI | 16.29 | |||||
| 3-1 Month Momentum % | -1.07 | |||||
| 6-1 Month Momentum % | -37.71 | |||||
| 12-1 Month Momentum % | -60.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.92 | |||||
| Quick Ratio | 2.8 | |||||
| Cash Ratio | 2.35 | |||||
| Days Sales Outstanding | 10.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.9 | |||||
| Shareholder Yield % | -90.16 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -29.44 | |||||
| Net Margin % | -39.78 | |||||
| FCF Margin % | -42.65 | |||||
| ROE % | -140.5 | |||||
| ROA % | -24.83 | |||||
| ROIC % | -48.96 | |||||
| 3-Year ROIIC % | 1937.14 | |||||
| ROC (Joel Greenblatt) % | -101.83 | |||||
| ROCE % | -30.27 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.35 | |||||
| PB Ratio | 5 | |||||
| Price-to-Tangible-Book | 8.33 | |||||
| EV-to-EBIT | 0.63 | |||||
| EV-to-EBITDA | 0.76 | |||||
| EV-to-Revenue | -0.23 | |||||
| EV-to-Forward-Revenue | 0.58 | |||||
| EV-to-FCF | 0.54 | |||||
| Price-to-GF-Value | 0.04 | |||||
| Price-to-Median-PS-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | 158.73 | |||||
| FCF Yield % | -118.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADAP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adaptimmune Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 178.032 | ||
| EPS (TTM) ($) | -0.314 | ||
| Beta | 2.35 | ||
| 3-Year Sharpe Ratio | -0.15 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 62.39 | ||
| 14-Day RSI | 16.29 | ||
| 14-Day ATR ($) | 0.047025 | ||
| 20-Day SMA ($) | 0.44325 | ||
| 12-1 Month Momentum % | -60.24 | ||
| 52-Week Range ($) | 0.246 - 1.65 | ||
| Shares Outstanding (Mil) | 257.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adaptimmune Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adaptimmune Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adaptimmune Therapeutics PLC Frequently Asked Questions
What is Adaptimmune Therapeutics PLC(ADAP)'s stock price today?
The current price of ADAP is $0.25. The 52 week high of ADAP is $1.65 and 52 week low is $0.25.
When is next earnings date of Adaptimmune Therapeutics PLC(ADAP)?
The next earnings date of Adaptimmune Therapeutics PLC(ADAP) is 2025-05-15 Est..
Does Adaptimmune Therapeutics PLC(ADAP) pay dividends? If so, how much?
Adaptimmune Therapeutics PLC(ADAP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers